Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 5.49%
As of Monday, July 13, Larimar Therapeutics, Inc.’s LRMR share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Commentary & Analysis
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 5.33%
As of Friday, July 10, Larimar Therapeutics, Inc.’s LRMR share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 8.73%
As of Thursday, July 09, Larimar Therapeutics, Inc.’s LRMR share price has surged by 8.73%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 13.16%
As of Thursday, July 09, Larimar Therapeutics, Inc.’s LRMR share price has surged by 13.16%, which has investors questioning if this is right time to sell.Omar Beirat
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 5.14%
As of Thursday, July 02, Larimar Therapeutics, Inc.’s LRMR share price has surged by 5.14%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $398.7 | $252.6 | 35% |
|
| Shares Out (Mil) | 90.3 | 52.3 | 60% |
|
| Institutional Ownership | 97.4% | 92.1% | 74% |
|
| Float (Mil) | 59.9 | 40.2 | 52% |
|
| Beta | 0.91 | 0.95 | 54% |
|
| Avg Daily Volume (000s) | 1,301 | 455 | 75% |
|
| Price Change (52-week) |
7.0% | 52.9% | 51% |
|
| Growth | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (31.3%) | (9.9%) | 13% |
|
| EPS (5yr) | 8.7% | 16.0% | 44 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (34.0%) | (15.6%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 7 | |
| Current EPS | ($0.376) | ($1.607) | ($1.180) | |
| Month Ago EPS | ($0.375) | ($1.608) | ($1.161) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | ($0.462) | ($2.112) | ($1.650) | |
| Year/Year Chg | 14.6% | (29.2%) | (67.8%) | |
| Financials | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($166) | ($43) | 8% |
|
| EPS (TTM) | ($2.088) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($131) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $3 | $5 | 21% |
|
| Enterprise Value (Q1) (Mil) | $164 | $180 | 25% |
|
| Valuation | LRMR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.53 | 2.56 | 59% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (87.7%) | (49.8%) | 6% |
|
| ROE | (109.8%) | (55.5%) | 9% |
|
| Liabilities to Assets | 24.2% | 30.3% | 16% |
|
| F-Score | 1 | 3 | 1% |
|
Larimar Therapeutics, Inc. did not pass any screens on 7/31/2026.
